[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gingival-bleeding\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gingival-bleeding":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,55,81,105,139,162,197,225],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100639359","efficacy-and-safety-of-ha35-gel-for-mild-gingival-recession-and-periodontal-inflammation-100639359",false,"NCT07577258","Efficacy and Safety of HA35 Gel for Mild Gingival Recession and Periodontal Inflammation","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate Efficacy and Safety of Topical 10% 35 kDa Hyaluronan (HA35) Gel for Mild Gingival Recession and Chronic Periodontal Inflammation","HA35-PERI","Inclusion Criteria:\n\n* Age 18-60 years, male or female\n* Clinically diagnosed with mild gingival recession (Miller Class I or II)\n* Chronic gingival pain, redness, swelling, or brushing-induced bleeding\n* Ability to complete self-assessments and comply with 42-day intervention\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Severe periodontitis, tooth mobility, or alveolar bone loss\n* Uncontrolled diabetes or immune dysfunction\n* Use of prescription periodontal medications within 2 weeks\n* Known hypersensitivity to hyaluronan or gel components\n* Oral infection, ulceration, or severe mucosal injury\n* Pregnant or lactating women","ALL","18 Years","60 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel in subjects with mild gingival recession and chronic periodontal inflammation. Eligible participants will apply the HA35 gel topically to the gingival and tooth surfaces twice daily for 42 consecutive days. The primary objectives are to assess changes in gingival recession, chronic gingival or radicular pain, gingival redness and swelling, and brushing-induced bleeding. Safety and local oral tolerability will be evaluated throughout the treatment period. This is a minimal-risk, non-pharmacological, non-invasive oral care intervention.",[28,29,30,31,32],"Mild Gingival Recession","Periodontal Inflammation","Chronic Gingival Pain","Gingival Redness and Swelling","Gingival Bleeding",[34,35,36,37,38,39,32,40,41,42],"Hyaluronan","35 kDa Hyaluronan","HA35","Gingival Recession","Periodontal Disease","Gingival Pain","Gingival Repair","Oral Care","Pilot Clinical Study","NOT_YET_RECRUITING","2026-05-07",{"date":46,"type":47},"2026-05-12","ACTUAL",{"date":49,"type":22},"2026-06-01",{"date":51,"type":22},"2026-08-01",{"name":53,"class":54},"Nakhia Impex LLC","INDUSTRY",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100624907","evaluation-of-a-toothpaste-containing-a-gum-health-active-in-participants-with-gingival-problem-100624907","NCT07415733","Evaluation of a Toothpaste Containing a Gum Health Active in Participants With Gingival Problem","A Randomized Clinical Study on the Effect of a Toothpaste Containing a Gum Health Active in Participants With Gingival Problem","Inclusion Criteria:\n\n* Participants need to be competent i.e., able to understand what is to take place and able to provide a free decision on agreeing to the activity\u002Ftaking part in the study on this.\n* Participants must be able to read and understand study instructions and any other relevant study documents.\n* Have at least 20 natural teeth without subgingival calculus, including 5 assessable teeth (excluding 3rd molars) in each quadrant.\n* Have a mean whole mouth BOP ≥ 10% at screening.\n* Willing to follow the lifestyle and dietary restrictions as detailed in the Information Sheet for study.\n\nExclusion Criteria:\n\n* Be pregnant or breastfeeding.\n* Participants who participated in gum health study within 3 months prior to screening.\n* Current participation in any other cosmetic studies, any dental clinical studies or clinical trials.\n* Participants who have used any gum health products in the 4 weeks prior to screening.\n* Obvious signs of untreated caries or significant periodontal disease, which in the opinion of the study dentist, will affect either the scientific validity of the study or if the participant to take part in the study would affect their wellbeing.\n* Have more than three sites with a probing pocket depth (PPD) of ≥ 5 mm.\n* Full or partial dentures wearers.\n* Current orthodontic treatment.\n* Smokers or those who have a recent smoking history, including e-cigarettes.\n* Diabetics.\n* Have had a dental prophylaxis in the month prior to enrolment or have one scheduled prior to the end of the study.\n* Medical condition and\u002For regular use of any medication which might affect the outcome of the study, as determined by the study dentist, principally a course of anti-inflammatory, antimicrobial or statin drugs within 4 weeks of screening.\n* Taking dietary supplements (e.g. multivitamins, antioxidants, fish oils, etc.).\n* Known allergy to any ingredient in study products.\n* The participant is a Unilever employee or a member of the study team.\n* Any participant who, in the judgement of the investigator, should not participate in the study.",true,{"count":64,"type":22},150,[25],"The primary objective of this clinical study is to evaluate the impact on gingival health when participants switch to a fluoride toothpaste without gum-health actives for 4 weeks after using a proven gum-health toothpaste for 13 weeks.",[68,32,69],"Gingival Inflammation","Dental Plaque","RECRUITING","2026-04-29",{"date":73,"type":47},"2026-04-30",{"date":75,"type":47},"2026-02-27",{"date":77,"type":22},"2026-08",{"name":79,"class":54},"Unilever R&D",1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":62,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":80},"100631497","comparison-of-the-effects-of-oral-hygiene-regimens-on-clinical-immunomodulatory-and-microbial-outcomes-and-oral-tolerance-in-people-with-gingivitis-100631497","NCT07501455","Comparison of the Effects of Oral Hygiene Regimens on Clinical, Immunomodulatory, and Microbial Outcomes and Oral Tolerance in People With Gingivitis","Inclusion Criteria:\n\n2\\. Adequate oral hygiene (i.e., brush teeth daily and exhibit no signs of gross oral neglect).\n\n3\\. Mean Modified Gingival Index (MGI) is greater than or equal to 2.00 at screening visit and reconfirmed at baseline visit.\n\n4\\. Bleeding upon probing (BOP) is greater than or equal to 30% at the screening visit.\n\n5\\. Diagnosis of gingivitis (confirmed by MGI and BOP) at the screening visit and reconfirmed at the baseline visit.\n\n6\\. Able to read and understand English. 7. Subject has signed the written informed consent (ICD) and indicated their agreement with the terms of the study and the study procedures listed and photograph release including the Health Insurance Portability and Accountability Act (HIPAA) disclosure prior to any study-related procedures.\n\n8\\. Generally, in good overall health based on the medical history reported by the subject.\n\n9\\. Has at least 18 natural teeth (not counting 3rd molars) with scorable facial and lingual surfaces.\n\n10\\. Willingness to use the assigned products according to instructions, availability for appointments, agreement to follow the subject responsibilities and likelihood of completing the clinical trial\n\nExclusion Criteria:\n\n1. Significant oral soft tissue pathology or active dental caries, based on the dentist's visual examination and at the discretion of the Investigator.\n2. History of significant adverse reactions, including sensitivity or suspected allergies, following use of oral hygiene products such as toothpastes, mouth rinses, and red food dye.\n3. Periodontitis, as determined by more than 2 sites with a probing depth greater than 4mm.\n4. Regular consumption of probiotics supplements within one week prior to screening. Subjects can be rescreened if they fulfill this criterion.\n5. Dental prophylaxis within 4 weeks prior to screening. Subjects can be rescreened if they fulfill this criterion.\n6. Subjects who wear orthodontic bands, fixed retainers, removable orthodontic appliances, clear aligners or night guards or subjects who have had significant (based on the examiner or PI's oral exam) cosmetic restorations.\n7. History of medical conditions requiring prophylactic antibiotic coverage prior to dental procedures.\n8. Self-reported tobacco, cannabis, smokeless tobacco use, including snuff, chewing tobacco, vaping, and e-cigarette usage.\n9. Suspected alcohol or substance abuse.\n10. Significant unstable or uncontrolled medical condition which may interfere with a subject's participation in the study, at the discretion of the Investigator, including a history of or a concurrent health\u002Fother condition\u002Fsituation which may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study.\n11. Has self-reported Type 1 or Type 2 diabetes or is on an anti-diabetic medication (i.e., metformin, insulin, Glucophage, etc.)\n12. Is taking a medication that would mask an Adverse Event (AE) or confound the study results, including:\n\n    * Non-steroidal anti-inflammatory drugs within 5 days before Visit 1 (81mg of aspirin is allowed).\\*\n    * Use of Immunosuppressive, or steroidal drugs therapy during the study or within 2 months before Visit 2. \\* Intermittent use (\\\u003C3 times per week) of certain anti-inflammatory medications is acceptable at the discretion of the investigator. Use of anticoagulant therapy within 1 month of screening visit or during the study.\n    * Use of systemic antibiotics within 1 month of screening visit and during the entire study.\n13. Is self-reported to be pregnant, in lactation, planning to become pregnant during the study, or positive pregnancy urine tests (females of child-bearing potential only):\n\n    * For females: Postmenopausal state (i.e., at least 1 year without menses without an alternative medical condition prior to the first study IP administration) or premenopausal\u002Fperimenopausal state with an effective means of contraception.\n    * Females of childbearing potential must be using a medically acceptable method of birth control for at least one month prior to Visit 1 and agree to continue using this method during their participation in the clinical trial. Medically acceptable forms of birth control that may be used by the subject and\u002For his\u002Fher partner include:\n\n      * Double barrier method (condoms, diaphragm or cervical cap with spermicide)\n      * Hormonal prescription contraceptives (i.e., oral, injectable, implanted, patch or vaginal ring hormone therapy)\n      * Intrauterine device (IUD)\n      * Surgical sterilization (e.g., vasectomy that has been confirmed effective by sperm count check, tubal ligation, hysterectomy and\u002For bilateral oophorectomy)\n      * Abstinence\n    * For males: No pregnant or lactating spouse or partner at screening and willingness to utilize an acceptable form of birth control with spouse or any potential partner during the study and for 30 days thereafter.\n14. Participation in any clinical trial within 30 days of the Screening visit.\n15. Subjects who were previously randomized into one of the study products as part of this study.\n16. Subjects who are related to the people who are involved directly or indirectly with the conduct of this study (i.e., principal Investigator, sub-investigators, study coordinators, other site personnel, employees of Kenvue, contractors of Kenvue, and the families of each).\n17. Subjects within the same household as other subjects enrolled in the study at the same time.",{"count":88,"type":22},250,[25],"This study is a six-week, double-blind, randomized, parallel-group controlled clinical study. The objective of this study is to evaluate the changes to the oral microbiome, inflammatory mediators, gingival health indices and to assess oral tolerance after 4 weeks of twice daily use of differing oral hygiene regimens including mouthwash compared to a control group. A follow-up assessment will be completed 2 weeks after cessation of treatments.",[92,93,94,95,32],"Microbiome","Cytokines","Plaque","Gingivitis","2026-03-26",{"date":98,"type":47},"2026-03-30",{"date":100,"type":47},"2026-02-26",{"date":102,"type":22},"2026-05-05",{"name":104,"class":54},"Kenvue Brands LLC",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":62,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":80},"100620972","the-antiplaque-and-antigingivitis-effect-of-pure-green-tea-mouth-wash-compared-to-placebo-and-essential-oils-mouth-washes-100620972","NCT07364565","The Antiplaque and Antigingivitis Effect of Pure Green Tea Mouth Wash Compared to Placebo and Essential Oils Mouth Washes","The Antiplaque and Antigingivitis Effect of Pure Green Tea Mouth Wash Compared to Placebo and Essential Oils Mouth Washes: A Double Blinded Randomized Controlled Clinical Trial.","Inclusion criteria:\n\n* Non-smokers\n* Systemically healthy\n* At least 24 teeth in the functional dentition, excluding third molars\n* Clinical diagnosis of periodontal health (no periodontal pockets \\> 3 mm, bleeding on probing percentage \\\u003C 10%, and no attachment loss).\n\nExclusion criteria:\n\n* Smokers.\n* Medically compromised patients.\n* Pregnant woman.\n* Allergies to green tea or EO.\n* Any condition that might affect the periodontal tissues.\n* Patients with any carious lesions (initial or active).\n* Patients who have overhang restorations, poorly designed crowns or bridges, and ortho retainers.\n* Use of systemic antibiotics or anti-inflammatory medications within 3 months prior to enrolment.",{"count":113,"type":22},44,[25],"The goal of this clinical trial is to to evaluate the antiplaque and antigingivitis effect of pure green tea mouthwash compared to placebo and essential oils mouthwashes in healthy patients.\n\nThe main questions it aims to answer are:\n\n* Does pure green tea mouthwash effectively reduce dental plaque?\n* Does pure green tea mouthwash reduce gingival inflammation?\n\nResearchers will compare pure green tea mouthwash to Listerine Total Care, Listerine Green Tea, and placebo to see if there is a difference in plaque accumulation and gum inflammation reduction.\n\nParticipants will be prohibited from using any sort of oral hygiene parctice for the whole study period (3 weeks). Instead, they will rinse with 10 ml of their assigned mouthwash twice daily for 30 seconds. Plaque index, gingival index, and staining index will be examined at multiple intervals and participants will rate their sense of oral freshness and good breath.",[69,117,118,68,32,95],"Patient Reported Outcome","Gingival Inflammation and Bleeding",[120,121,122,123,124,125,126,127,128],"Green tea","Gingival inflammation","Plaque index","Essential oils","Mouthwash","Bleeding on probing","Camellia sinensis","Herbal medicine","Periodontal health","2026-01-21",{"date":131,"type":47},"2026-01-23",{"date":133,"type":47},"2025-12-01",{"date":135,"type":22},"2026-12",{"name":137,"class":138},"King Abdullah University Hospital","OTHER",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":62,"sex":17,"minAge":18,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":80},"100612622","phase-4-comparison-of-effectiveness-of-gingival-displacement-using-retraction-cord-and-aluminum-chloride-gel-100612622","NCT07255976","Comparison of Effectiveness of Gingival Displacement Using Retraction Cord and Aluminum Chloride Gel","Inclusion Criteria:\n\n1. age ranges from 18 to 50 years a fixed prosthesis with minimum of two abutments.\n2. minimum of two abutments\n3. Finishing line margins will be Equiogingival\n4. Clinically healthy gingiva and periodontium.\n\nExclusion Criteria:\n\n* 1\\. Sub-gingival or supra-gingival margins 2 Periapical pathosis 3. inadequate obturated root canals 4. bleeidng disorder 5.uncontrolled diabetes, 6.hypertension 7.neurological disease","50 Years",{"count":147,"type":22},66,[149],"PHASE4","This study aims to compare the horizontal gingival displacement by using a retraction cord and aluminum chloride gel, and also to determine the time taken for placement and hemorrhage after the procedure by using a retraction cord and aluminum chloride gel. Patients of both genders, age ranges from 18 to 50 years, will be selecting requiring fixed prosthesis with of minimum two abutments. This study divided in two parallel groups of 33 patients in each group.",[32,152,153],"Prosthesis Failure, Dental","Tissue Injury","2025-11-27",{"date":133,"type":47},{"date":157,"type":47},"2024-09-11",{"date":159,"type":22},"2025-12-30",{"name":161,"class":138},"Dow University of Health Sciences",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":62,"sex":17,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":23,"phases":173,"briefSummary":174,"conditions":175,"keywords":179,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":80},"100550894","comparative-evaluation-of-smart-hall-technique-vs-conventional-ss-crown-in-primary-molars-a-randomized-clinical-trial-100550894","NCT06453005","Comparative Evaluation of SMART Hall Technique Vs. Conventional SS Crown in Primary Molars: a Randomized Clinical Trial","Comparative Evaluation of SMART Hall Technique Versus Conventional SS Crown Restoration in Treatment of Carious Primary Molars - a Randomized Clinical Trial","RCT","Inclusion Criteria:\n\n1. Children aged 3 to 9 years old.\n2. Presence of occluso-proximal carious lesions (ICDAS CODE 3\u002F4\u002F5) in one or more primary molars, confirmed through clinical examination and radiographic assessment.\n3. Requirement for restorative treatment in the form of either the SMART Hall technique or standard stainless steel crown (SSC) restoration, as determined by clinical assessment.\n4. Willingness and ability of the parent\u002Fguardian to provide informed consent and ensure the child's attendance at follow-up appointments.\n5. Adequate cooperation of the child during dental treatment and evaluation procedures, as determined by the clinician.\n\nExclusion Criteria:\n\n1. Presence of severe systemic medical conditions (e.g., uncontrolled diabetes, immunodeficiency disorders) that may compromise treatment outcomes or pose risks during dental procedures.\n2. Use of medications known to interfere with dental treatment or healing, such as anticoagulants or immunosuppressants, unless medically managed and deemed safe by the treating healthcare provider.\n3. History of adverse reactions to dental materials or procedures that may contraindicate participation in the study.\n4. Inability of the child to tolerate local anesthesia or undergo dental treatment due to psychological, behavioral, or developmental factors.\n5. Presence of extensive dental caries or additional oral pathologies requiring urgent or specialized dental care beyond the scope of the study.","3 Years","9 Years",{"count":21,"type":22},[25],"Dental caries, particularly in primary molars, significantly affects children's oral health and overall well-being. Traditional management with stainless steel crowns (SSCs) involves significant tooth reduction and advanced dental skills. Introduced in the 1970s, the Hall technique offers a less invasive alternative, minimizing tooth reduction compared to SSCs.\n\nThe SMART Hall technique represents a further evolution, emphasizing atraumatic cavity preparation using hand instruments. It offers advantages like minimal or no tooth reduction, minimized discomfort, improved patient cooperation, shorter treatment times, and cost-effectiveness.\n\nSilver Diamine Fluoride (SDF) emerges as a promising non-invasive approach for managing dental caries in primary teeth, though it may cause temporary tooth discoloration. However, comparative evaluation with traditional SSC restorations remains limited.\n\nTo address this gap, a randomized clinical trial will evaluate the treatment outcomes of the SMART Hall technique versus conventional SSC restoration for managing occluso-proximal carious lesions (ICDAS CODE 3\u002F4\u002F5) in primary molars of young patients. Children aged 3 to 9 years requiring restorations will be included, assessing clinical outcomes, treatment time duration, and radiographical outcomes of both techniques at specific follow-up intervals of 3 months \\& 6 months.\n\nThis split mouth study will explore Clinical outcomes, radiographical outcomes, treatment time duration, and patient's pain perception with the chosen treatment modality. The findings will provide insights into the effectiveness and feasibility of the SMART Hall technique compared to the traditional SSC approach, informing evidence-based decision-making in pediatric dentistry and influencing treatment recommendations for preserving the health and function of primary molars in young children.",[176,177,178,32],"Caries,Dental","Pain","Plaque, Dental",[180,181,182,183,184,185,186,187],"Randomized Clinical Trial","Dental caries","Primary molars","Stainless Steel Crowns","SMART Hall Technique","Conventional Technique","Silver Diamine Fluoride","Split Mouth Study","2025-02-27",{"date":190,"type":47},"2025-03-03",{"date":192,"type":47},"2024-01-30",{"date":194,"type":22},"2025-04-01",{"name":196,"class":138},"C K S Teja Institute Of Dental Sciences & Research",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":62,"sex":17,"minAge":18,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":80},"100575976","adjunctive-oral-hygiene-aids-in-reducing-oral-hygiene-parameters-among-orthodontic-patients-100575976","NCT06779279","Adjunctive Oral Hygiene Aids in Reducing Oral Hygiene Parameters Among Orthodontic Patients","Adjunctive Oral Hygiene Aids in Reducing Commonly Seen Oral Hygiene Parameters Among Orthodontic Patients: a Randomized Controlled Trial","D-F-H-17-Dec","Inclusion Criteria:\n\n* Participants aged 18-35 years undergoing orthodontic treatment and\n* systemically healthy without habits\n\nExclusion Criteria:\n\n* Participants not undergoing orthodontic treatment and participants undergoing orthodontic treatment in the included age category but with systemic conditions prevalent\n* missing teeth and\n* treated previously for periodontal conditions","35 Years",{"count":207,"type":22},102,[25],"Adult orthodontic patients aged 18-30 were included in a randomised, singleblind clinical research using a split-mouth design at a dental clinic. Both theWaterflosser® and the Super-Floss® water flossers are manufactured by Oral-B.",[32,211],"Dental Plaque Accumulation",[213,214,215,69],"waterflosser","superfloss","gingival bleeding","2025-01-19",{"date":218,"type":47},"2025-01-22",{"date":220,"type":22},"2025-02-10",{"date":222,"type":22},"2025-03-26",{"name":224,"class":138},"sudhir rama varma",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":62,"sex":17,"minAge":232,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":23,"phases":236,"briefSummary":237,"conditions":238,"keywords":242,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":80},"100553791","evaluation-of-nonsurgical-treatment-of-deep-periodontal-pockets-7-10mm-using-airflow-prophylaxis-master-device-with-erythritol-powder-vs-conventional-instrumentation-100553791","NCT06490679","Evaluation Of Nonsurgical Treatment Of Deep Periodontal Pockets (7-10mm) Using AIRFLOW® Prophylaxis Master Device With Erythritol Powder vs Conventional Instrumentation","Evaluation Of Nonsurgical Treatment Of Deep Periodontal Pockets (7-10mm) Using AIRFLOW® Prophylaxis Master Device With Erythritol Powder vs Conventional Instrumentation: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Systemically healthy patients.\n* Patients with an age range between 16 to 80 years.\n* Patients have a minimum of 20 teeth.\n* Periodontitis patients with at least one residual pocket with a probing depth ranging from 7 to 10 mm.\n* Cooperative patients able and willing to come for follow up appointments.\n\nExclusion Criteria:\n\n* Pregnant and lactation females.\n* Patients reporting systemic conditions (eg: diabetes).\n* Patients with severe or unstable upper respiratory tract infections, chronic bronchitis\u002Fasthma.\n* Patients with severe inflammation and\u002For osteonecrosis.","16 Years","80 Years",{"count":235,"type":22},46,[25],"Periodontitis is a chronic condition associated with the inflammatory destruction of the periodontal tissues ultimately leading to tooth loss. Clinically, it is identified by key features such as clinical attachment loss (CAL), bleeding upon probing (BOP), and an increase in probing pocket depth (PPD), and\u002For gingival recession. Periodontitis is mediated by polymicrobial dysbiosis with keystone pathogens affecting the virulence of the entire biofilm community. The removal of this biofilm and its retention factors is the ultimate goal of clinical treatment and oral measures applied. The elimination of the biofilm has traditionally been achieved with the use of either hand instruments or power driven devices. Promoting periodontal health or diminishing bacterial presence and calculus buildup on teeth can be accomplished with the same efficacy whether using manual scalers and curettes or ultrasonic scaling instruments. Both hand and ultrasonic instruments are characterized by being time- consuming and requiring technical skill, often causing patient discomfort and post-treatment pain, including hypersensitivity resulting from the loss of hard tissue when scaling the tooth surface. Ultrasonic instruments tend to leave a rougher surface behind compared to hand instruments. While effective the current techniques all have their disadvantages. The aim of this study is to evaluate changes in probing depth clinically, Bleeding on probing, Clinical attachment level, Plaque index, Calculus index, Patient pain\u002Fdiscomfort, Patient satisfaction, Cost effectiveness, Treatment time and Number of pockets closed after using AIRFLOW® Prophylaxis Master device with erythritol powder.",[239,240,241,32],"Periodontal Pocket","Periodontitis","Gingival Diseases",[243,244],"Air Abrasive","Erythritol","2024-08-07",{"date":247,"type":47},"2024-08-09",{"date":249,"type":47},"2024-03-01",{"date":251,"type":22},"2026-01-01",{"name":253,"class":138},"Cairo University"]